EXCLUSIVE: Oragenics' Concussion Drug Clears FDA-Required Cardiotoxicity Testing, Planning For Phase II Trials Underway
Portfolio Pulse from Vandana Singh
Oragenics Inc. (NYSE:OGEN) announced that its concussion drug, ONP-002, has cleared FDA-required cardiotoxicity testing, indicating it does not cause cardiotoxicity. The company is planning Phase 2 trials to assess the drug's safety and effectiveness. The stock was trading higher by 4.50% premarket.
August 08, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Charles River Laboratories (NYSE:CRL) conducted the hERG ion channel studies for Oragenics' ONP-002 under Good Laboratory Practices (GLP), contributing to the successful cardiotoxicity testing results.
Charles River Laboratories' involvement in the successful cardiotoxicity testing of ONP-002 highlights its role in the drug development process, potentially boosting its reputation and investor confidence.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
Oragenics' concussion drug ONP-002 has cleared FDA-required cardiotoxicity testing, indicating it does not cause cardiotoxicity. The company is planning Phase 2 trials to assess the drug's safety and effectiveness. The stock was trading higher by 4.50% premarket.
The successful completion of FDA-required cardiotoxicity testing is a significant milestone for Oragenics' ONP-002, increasing investor confidence and driving the stock price up by 4.50% premarket. The planned Phase 2 trials further add to the positive outlook.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100